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In-hospital and 30-day outcomes after
tibioperoneal interventions in the US Medicare
population with critical limb ischemia
Todd R. Vogel, MD, MPH, Viktor Y. Dombrovskiy, MD, PhD, MPH, Jeffrey L. Carson, MD, and
Alan M. Graham, MD, New Brunswick, NJ
Objectives: Catheter-based revascularization has emerged as an alternative to surgical bypass for the tibioperoneal vessels.
The purpose of this analysis was to describe the outcomes of tibial angioplasty interventions for critical limb ischemia
(CLI) in the hospitalized Medicare population, to examine in-hospital complications, to define the 30-day readmission
and mortality rates, and to assess secondary procedures performed in this population.
Methods: In-patients with CLI undergoing tibioperoneal angioplasty were identified using The Centers for Medicare &
Medicaid Services in-patient claims for 2005 to 2007. In-hospital complications, mortality, 30-day secondary procedures,
and 30-day rehospitalization after discharge were described.
Results: A total of 13,258 in-patients underwent tibioperoneal angioplasty (54.2% men; 75.7% white, 17.1% African
American; 42.8% gangrene, 46.7% rest pain, 10.5% claudication) and 29.3% had a stent, 47.3% had femoral-popliteal
angioplasty, and 20.1% had atherectomy during their initial procedure. Initial hospital complications included renal
complications (8.1%), respiratory complications and pneumonia (5.1%), and cardiac complications with acute myocardial
infarction (3.2%). Mortality in-hospital was 2.8% and at 30 days was 6.7%. Thirty-day rehospitalization rate was 29.6%.
Thirty-day reinterventions included repeat angiogram (8.5%), repeat tibioperoneal angioplasty (3.2%), open bypass
(2.1%), and lower extremity amputations (23.8%). Gangrene was the most frequent diagnosis at rehospitalization
(13.5%). Patients with gangrene as an indication for tibioperoneal angioplasty were 1.8 times (95% confidence interval
[CI], 1.56-2.10) as likely as patients with rest pain to be rehospitalized during 30 days after discharge. Among
comorbidities, predictors of 30-day rehospitalization included chronic renal failure (odds ratio [OR], 1.4; 95% CI,
1.27-1.52), chronic pulmonary disease (OR, 1.1; 95% CI, 1.01-1.25), and congestive heart failure (CHF; OR, 1.1; 95%
CI, 1.01-1.22). About one-quarter of patients (23.8%) within 30 days after their initial procedure underwent amputation
at any level of the lower limb.
Conclusion: Tibioperoneal angioplasty is associated with frequent in-hospital complications, an overall 30-day amputa-
tion rate of 23.8% for all procedures and indications, and a 30-day rehospitalization rate of almost 30%. Further detailed
analysis of tibioperoneal intervention is essential to define best treatment strategies and to minimize complications and
readmission rates. ( J Vasc Surg 2011;54:109-15.)
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2The utilization of lower extremity angioplasty has in-
creased over the past several years,1-4 particularly the use of
tibioperoneal angioplasty for critical limb ischemia (CLI).
Currently, little population data evaluating tibioperoneal
angioplasty exists and the longitudinal outcomes after these
interventions occur are largely unknown. This article uti-
lized the anatomic specificity of level of intervention of
current procedural terminology (CPT) codes to evaluate
the US Medicare population for 30-day longitudinal out-
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doi:10.1016/j.jvs.2010.12.055omes after tibioperoneal angioplasty of the lower extrem-
ty for CLI.
As the cost of healthcare continues to rise dramatically
nd the proportion of elderly patients continues to rise,5
here is a significant need for evidence-based evaluation of
he endovascular management of the lower extremity for
LI. We hypothesized that the amputation rates after
ibioperoneal interventions remained high after tibioper-
neal angioplasty for CLI. The purpose of this study was to
nalyze the outcomes after tibioperoneal angioplasty for
LI in the hospitalized Medicare population, to examine
he in-hospital complications, to describe the 30-day read-
ission and mortality rates, and to provide a population-
ased descriptive analysis of secondary procedures and am-
utations by level performed in this population after
ibioperoneal intervention.
ETHODS
Data sources. Data for this study were collected from
he Centers for Medicare & Medicaid Services Medicare
rovider Analysis and Review and Carrier files for the years
005 to 2008. TheMedicare Provider Analysis and Review
le includes patient demographics, clinical information (di-
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July 2011110 Vogel et alagnoses and procedures performed), and hospitalization
characteristics. The Carrier file allows for the identification
of procedure utilizing the CPT code and the date of its
performance. Each claim in both databases includes unique
patient identifier that make possible to follow-up patient
hospitalizations over time.
Study population. Hospitalized Medicare beneficia-
ries aged 65 years and older with CLI who underwent
tibioperoneal percutaneous transluminal angioplasty
(PTA) during the years 2005 to 2007 were selected utiliz-
ing the International Classification of Disease, 9th Revi-
sion, Clinical Modification (ICD-9-CM) principal diagno-
sis codes for rest pain (440.22), ulceration (440.23,
707.10, 707.12-707.19), or gangrene (440.24, 785.4)
and CPT code 35470 (percutaneous transluminal balloon
angioplasty of the tibioperoneal trunk or branches). We
included in the initial cohort only patients with cases that
were first documented in each year. Also, if the same patient
had several tibioperoneal PTAs within the study time, only
the first documented case was included in the initial cohort.
We followed up study patients for 1 month after discharge.
Because some interventions occurred at the end of the year
2007 and the patients were discharged in 2008, we used the
longitudinal analysis of these cases also for the Centers for
Medicare & Medicaid Services data in 2008. Using addi-
tional CPT codes, we recognized the following concomi-
tant procedures during initial tibioperoneal PTA: angio-
gram (36140, 36200, 36245, 36246, 36247, and 36248),
iliac PTA (35473), femoral-popliteal PTA (35474), trans-
catheter intravascular stenting (37205), and transluminal
tibioperoneal atherectomy (35495). Complications during
the initial hospitalization were evaluated primarily with the
ICD-9-CM diagnosis codes associated with complications
of surgical and medical care: cardiac complications and
acute myocardial infarction (997.1, 410.xx, 427.5), respi-
ratory complications and pneumonia (997.3x, 480.x, 481,
482.0-482.2, 482.3x, 482.4x, 482.8x, 482.9, 483.x,
484.x, 485, 486, 507.0, 512.1, 518.4, 518.5, 518.81, and
518.82), and renal complications including acute renal
failure and failure specified as due to procedure (997.5 and
584.x). Complications within this cohort were primarily
identified from “997” codes in the data set which are
defined as “Complications of Surgical and Medical Care,”
suggesting that ICD-9 coding criteria for these events
occurred during the hospitalization as secondary events.
Codes analyzed as complications were not contained in the
principal diagnosis code position, which is generally con-
sidered the reason for admission. We have also included
acute conditions (acute myocardial infarction, pneumonia,
and acute renal failure) that were coded as secondary diag-
noses and were not the reason for the current hospitaliza-
tion.
With the above-mentioned CPT codes for surgical
procedures, we evaluated whether the same procedure was
repeated during 30 days after initial procedure perfor-
mance. Using the appropriate CPT codes, we also recog-
nized other surgical reinterventions that may be required
during the same period, such as open distal bypass (35556, g5566, 35583, 35585, 35656, 35666, 35226, 35256, and
5286), lower extremity amputation above (27590,
7591, and 27592) and below (27880, 27881, and
7882) the knee, ankle/foot/toe amputation (28800,
8805, 28810, 28820, and 28825), thrombolysis (37201,
7202), embolectomy (37184, 37185, 35302, 35303,
5304, 35305, 35306, 34201, and 34203), and fas-
iotomy (27600, 27601, and 27602). All readmissions are
aptured as they are contained in the Medicare billing data
nd are captured at any location in the United States. To
nalyze comorbidities in the study population, we used
gency for Healthcare Research and Quality comorbidity
easures that were initially created by Elixhauser et al6 and
ased on the ICD-9-CM codes for secondary diagnoses.
Statistical analysis. All data analysis, including statis-
ics, was performed with SAS 9.2 software (SAS Institute,
ary, NC). Hospital mortality was calculated as a number
f persons who died during the initial hospitalization di-
ided by the number of patients undergoing an interven-
ion and expressed as a percentage. We also computed a
0-day mortality rate as a number of persons who died
uring 30 days after initial procedure divided by the num-
er of patients undergoing an intervention and also ex-
ressed as a percentage. Thirty-day rehospitalization rate
as calculated as a number of persons who were rehospi-
alized for any reason and at any hospital during 30 days
fter initial discharge divided by the number of persons who
ere discharged alive after the initial procedure. We calcu-
ated the 30-day reintervention rate as the number of
ersons who underwent additional revascularization or
ther related surgical procedure during 30 days after initial
TA divided by the total cohort. Both these rates were
xpressed as a percentage. To test the difference between
he two groups we used 2 analysis. Multivariable logistic
egression analysis with forward stepwise approach calcu-
ating the odds ratio (OR) with 95% confidence interval
CI) was used to identify risk factors for various outcomes,
ncluding postintervention complications, rehospitaliza-
ion, amputations, and mortality. Adjustment was made for
atient sociodemographic characteristics, indications for
urgical procedure, and selected Agency for Healthcare
esearch andQuality comorbidities. A value of P .05 was
onsidered statistically significant. The study was approved
y the Institutional Review Board of the University of
edicine and Dentistry of New Jersey – Robert Wood
ohnson Medical School.
ESULTS
A total of 13,258 patients who met our inclusion
riteria were identified; their characteristics are displayed in
he Table. Octogenarians accounted for more than two-
fths of the study population. Approximately one-quarter
f all patients were under the age of 70. Men were greater
n the cohort compared to women (P  .0002). The
ajority of the angioplasty patients were white followed by
frican Americans and Hispanics. The most frequent indi-
ations for tibioperoneal PTA were ulceration and gan-
rene; patients with rest pain accounted only for one-tenth
a
c
t
a
a
(
e
w
t
s
e
w
m
(
P
r
t
w
u
l
t
m
t
l
r
m
p
(
y
w
p
t
p
h
(
w
F
p
t
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 1 Vogel et al 111of the study cohort. More than half of the study population
underwent isolated tibioperoneal PTA. Almost 30% of the
procedures were combined with stenting, and approxi-
mately one-fifth of the cases of tibioperoneal PTA were
combined with atherectomy. In 47.3% of the cases of
tibioperoneal PTA, the procedure was combined with
femoral-popliteal PTA and 3% of patients underwent
tibioperoneal PTA in combination with iliac PTA.
Postintervention complications that were selected for
this analysis were noted to occur in 14% of the cohort. Of
the patients identified as having any complication, 15.5%
had more than one complication occur using the pre-
defined ICD-9 complication codes. Renal complications
occurred at the greatest rate (8.1%), followed by respiratory
(5.1%) and cardiac (3.2%) complications. Frequency distri-
bution of postintervention complications in patients with
tibioperoneal PTA and different indications is presented in
Fig 1. The proportion of all postintervention complications
in patients with gangrene was significantly greater com-
pared with patients with ulceration (P .0002) or rest pain
(P  .0002). The greatest rates of renal, respiratory, and
cardiac complications were also found in patients with
gangrene and all complications were significantly greater
compared with patients with rest pain (P  .0002 for all).
Renal complications were found to be significantly lower in
Table. Characteristics of study population and
procedures performed
Characteristic No. of patients %
Age, years
Mean  SD 77.1  8.6
65-69 3288 24.8
70-74 1963 14.8
75-79 2467 18.6
80-84 2592 19.6
85 and above 2948 22.2
Gender
Male 7186 54.2
Female 6072 45.8
Race
White, non-Hispanic 10,043 75.7
African American, non-Hispanic 2265 17.1
Hispanic 489 3.7
Other 425 3.2
Unknown 36 0.3
Indications
Gangrene 5668 42.8
Ulcer 6192 46.7
Rest pain 1398 10.5
Level of procedure
TP 6638 50.1
TP  femoral-popliteal 6273 47.3
TP  iliac 347 2.6
Type of procedure
AP (angioplasty) only 7165 54.1
AP  stent 3426 25.8
AP  atherectomy 2204 16.6
AP  stent  atherectomy 463 3.5
Total 13,258 100
AP, Angioplasty; TP, tibioperoneal only.patients with an indication of rest pain compared to ulcer- (tion (P .0002). Rates of respiratory and cardiac compli-
ations did not differ significantly between these indica-
ions. In multivariable logistic regression analysis with
djustment by age, gender, race, indications for procedure,
nd comorbidities, patients with gangrene were three times
95% CI, 2.4-3.8; P  .001) as likely to have any postint-
rvention complication as patients with ulceration who
ere in turn 1.5 times as likely to have complications as
hose with rest pain (95% CI, 1.2-1.9; P  .0003). The
ame analysis discovered the greater likelihood of postint-
rvention complications in African Americans compared to
hites (OR, 1.18; 95% CI, 1.03-1.36; P  .02).
In-hospital mortality was 2.78%. The greatest hospital
ortality was found among patients with gangrene
4.18%); in those with an ulceration, it was lower (1.86%;
 .0002) and tended to further decrease in patients with
est pain (1.22%; P .097). Mortality during 30 days after
he initial procedure was 6.73%. Its highest level (9.49%)
as also found among patients with gangrene; in those with
lceration, it was lower (4.97%; P .0002) and it was even
ess in patients with rest pain (3.29%; P  .007). A similar
rend remained when we analyzed hospital and 30-day
ortality rates in logistic regressionmodel withmortality as
he outcome (Fig 2). In both models, women were more
ikely to die than men; congestive heart failure (CHF) and
enal failure were significant predictors for both mortality
easures. Risk-adjusted 30-day mortality among the oldest
atients (85 years old and above) was significantly greater
OR, 1.35; 95% CI, 1.1-1.67; P  .005) than in the
oungest (65-69 years old) patients. Interestingly, whites
ere more likely to die during the 30 days after their
rocedure compared to African Americans.
A total of 3814 patients (29.6% of patients undergoing
ibial intervention who were discharged alive) were rehos-
italized during 30 days after discharge. The greatest re-
ospitalization rate was among patients with gangrene
37.0%); rehospitalization was significantly less in patients
ith ulceration (24.7%; P .0002) and those with rest pain
ig 1. Postoperative complications in patients with tibioperoneal
ercutaneous transluminal angioplasty (PTA) and different indica-
ions.22.2%; P  .0002). Gangrene was the most frequent
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July 2011112 Vogel et alprincipal diagnosis at rehospitalization (13.5%) followed by
diabetes type II with circulatory disorders and other mani-
festations (11.8%), heart failure (5.3%), septicemia (5.2%),
and atherosclerosis of extremities with ulceration (4.1%). In
the logistic regression model with adjustment by age, gen-
der, race, indication for PTA, and comorbidities, rehospi-
talization during 30 days after tibioperoneal PTA because
of gangrene was still more likely compared to procedure for
rest pain (OR, 1.82; 95% CI, 1.56-2.10; P .0001). Other
risk factors for 30-day rehospitalization were CHF (OR,
1.11; 95% CI, 1.01-1.22; P  .025), chronic pulmonary
disease (OR, 1.13; 95%CI, 1.01-1.25; P .034), and renal
failure (OR, 1.39; 95% CI, 1.27-1.52; P  .0001).
Fig 3 displays frequency distribution of secondary sur-
gical procedures that were performed during the 30 days
after initial tibioperoneal PTA. Angiogram was the most
frequent procedure followed by repeated tibioperoneal and
femoral-popliteal PTA. In some cases, there was a necessity
of additional stenting (2.4%), bypass (2.13%), or atherec-
Fig 2. Risk factors of hospital and 30-day mortality after tibioper-
oneal percutaneous transluminal angioplasty (PTA). CHF, Con-
gestive heart failure; CI, Confidence interval; OR, odds ratio.
Fig 3. Reinterventions during 30 days after tibioperoneal percu-
taneous transluminal angioplasty (PTA).tomy (1.58%). Secondary thrombolysis, embolectomy, iliac rTA, or fasciotomy during this period of time were per-
ormed in 1% of patients undergoing tibioperoneal PTA.
As a whole, 30-day amputation rate at any level was
qual to 23.8%. As expected, the greatest rate (44.2%) was
ound in patients with gangrene; it was lower in patients
ith ulceration (9.6%; P  .0002), and the lowest ampu-
ation rate after PTA was for rest pain (3.9%; P  .0002).
e also analyzed 30-day rates of lower extremity amputa-
ions at various levels such as above knee, below knee, and
nkle/foot/toe (Fig 4). Rates of above and below knee
mputations (BKAs) in patients with gangrene were signif-
cantly greater than in patients with ulceration or rest pain
P .0002); the latter two rates did not differ significantly.
he rate of ankle/foot/toe amputations was found to be
inimal in patients with a diagnosis of rest pain at 30 days.
t significantly increased in those with ulceration (P 
0002) and was extremely high in patients with gangrene
P  .0002).
Further subset analysis was performed of the cohort to
valuate the implications for amputation rates with regard
o isolated tibioperoneal PTA compared to multilevel dis-
ase and interventions. In the cohort, 6638 were found to
ave undergone isolated tibioperoneal PTA compared to
620 who underwent multilevel/tibioperoneal PTA.
verall, women were more likely to undergo multilevel/
ibioperoneal PTA (55.6%) compared to men (45.2%). Of
he patients undergoing multilevel/tibioperoneal PTA,
4.8% had concomitant femoral-popliteal intervention and
.2% underwent a concomitant iliac intervention combined
ith their tibial PTA. Further evaluation of the 30-day
mputation rates of these subsets was performed. Patients
eceiving isolated tibioperoneal PTA had significantly lower
ates of 30-day above-the-knee amputations compared to
hose undergoing multilevel/tibioperoneal PTA (2.6% vs
.4%; P .0046). Evaluation of 30-day BKA rates demon-
trated that isolated tibioperoneal PTA had significantly
igher rates of amputation compared to multilevel/tib-
operoneal PTA (7.2% vs 4.8%; P  .0002). Finally, with
ig 4. Thirty-day amputation rates for various indications for
ibioperoneal percutaneous transluminal angioplasty (PTA).egard to the rates of ankle/foot/toe amputations at 30
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Volume 54, Number 1 Vogel et al 113days, isolated tibioperoneal PTA had significantly higher
rates compared to multilevel/tibioperoneal PTA (17.1% vs
15.7%; P  .03).
Realizing that gangrene is an indication for amputa-
tion, we utilized multivariable logistic regression analysis to
identify sociodemographic characteristics of patients and
comorbidities that might be the additional risk factors for
30-day amputation (Fig 5).
DISCUSSION
Over the last decade dramatic shifts in the management
of peripheral vascular disease have occurred.4 This analysis
has demonstrated on a population level using the US
Medicare population that tibioperoneal angioplasty is asso-
ciated with a 30-day readmission rate after discharge of
almost 30% and that the rate of a second angiogram within
30-days is 8% in the entire cohort. We have also demon-
strated that overall, almost one-quarter of the patients
treated with tibioperoneal PTA will succumb to amputa-
tion after their initial procedure within 30 days, perhaps
representing a sicker cohort of all comers seen in the
population level data. The amputations have been reported
by level and the possibility that some amputations may have
been planned cannot be excluded as this analysis is based on
population-level administrative data, which lack detailed
clinical information and individual scenarios. Nonetheless,
we have also demonstrated an 11.6% 30-day BKA rate for
patients undergoing tibioperoneal angioplasty with gan-
grene as their original diagnosis and a 30-day ankle, foot, or
toe amputation rate of 7.2% for patients presenting with
ulceration who underwent tibioperoneal angioplasty.
Authors have suggested that minimally invasive revas-
cularization strategies for chronic lower limb ischemia offer
early success rates, but long-term follow-up is needed to
make confident remarks about the effectiveness of these
techniques. Giles et al7 reported that infrapopliteal angio-
plasty is a reasonable primary treatment for CLI in a cohort
Fig 5. Risk factors for 30-day amputations after tibioperoneal
percutaneous transluminal angioplasty (PTA). CHF, Congestive
heart failure.of 176 consecutive limbs with an average follow-up of 10 aonths. They concluded that although restenosis, reinter-
ention, or amputation rates are high after tibial angio-
lasty for CLI, excellent limb salvage rates may be obtained
ith careful follow-up and reinterventions when necessary.
reedom from restenosis, reintervention, or amputation in
and 2 years was 39% and 35%, respectively, and unsuit-
bility for surgical bypass also predicted restenosis, reinter-
ention, and amputation.
Kudo et al8 evaluated the effectiveness of percutaneous
ransluminal angioplasty for the treatment of CLI and
valuated 138 limbs in 111 patients with CLI (rest pain in
5% and ulcer/gangrene in 55%) with a mean follow-up of
4.7 months. They reported a primary patency of 23.5%
nd continued clinical improvement in 51.1% of the tibial
nterventions. Tefera et al9 evaluated limb salvage after
ngioplasty in a retrospective clinical analysis of 67 consec-
tively treated patients (76 limbs) with CLI over a 33-
onth period. They quoted a clinical failure of approxi-
ately 16% and this correlated with the presence of
angrene or the combination of diabetes, arterial occlusion,
nd gangrene.
Our analysis has demonstrated that within the entire
edicare population and a shorter time interval, the overall
0-day amputation rate after tibioperoneal PTAwas 23.8%.
s well, we have demonstrated that almost 30% of these
atients are readmitted with the most common diagnoses
elated to ischemia, infection, and gangrene. Subset analy-
is demonstrated that patients receiving isolated tibioper-
neal PTA had significantly lower rates of 30-day above-
he-knee amputations compared to those undergoing
ultilevel/tibioperoneal PTA. In addition, evaluation of
0-day BKA and ankle/foot/toe amputations rates dem-
nstrated that isolated tibioperoneal PTA had significantly
igher amputation rates compared to multilevel/tibioper-
neal PTA. This finding suggests that patients with com-
ined inflow and tibial lesions have improved limb salvage
ompared to isolated tibioperoneal disease.
The Bypass versus Angioplasty in Severe Ischaemia of
he Leg (BASIL) trial was performed as a multicenter
andomized controlled trial to evaluate CLI. This analysis
emonstrated that surgical bypass vs PTA did not differ
ignificantly in amputation-free survival for CLI. This study
eported no difference in health-related quality of life be-
ween the two strategies, but for the first year, the hospital
osts associated with a surgery-first strategy were about
ne-third higher than those with an angioplasty first strat-
gy.10 Comparison of this administrative data study to the
ASIL trial population is provided as a possible reference as
here are limited studies with short-term follow-up. The
ASIL trial reported 46 events or approximately a 20%
vent rate for amputation-free survival and an all-cause
ortality at 6 months for patients undergoing balloon
ngioplasty. This Medicare analysis has reported mortality
0 days after the initial procedure of 6.73% and a 30-day
mputation rate at any level of 23.8% for CLI. When the
opulations are compared in the BASIL trial, approxi-
ately 25% had rest pain and 75% had tissue loss. In this
nalysis of the Medicare population, almost 90% had tissue
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July 2011114 Vogel et alloss and approximately 10% had rest pain as documented by
their ICD-9 codes. The BASIL trial reported a rate of
diabetes of 42% and the Medicare population in this anal-
ysis had an overall rate of diabetes of 46% and a rate of
patients with renal failure of 32%. The Medicare popula-
tions identified in this study undergoing tibioperoneal an-
gioplasty seem to have higher rates of tissue loss, higher
rates of diabetes, and were older overall. This disparity may
account for the higher amputation rates seen in this analysis
compared to the BASIL trial. This is not a randomized trial,
but a population-based analysis and patients who are more
severely ill or have more severe advanced disease may be
more likely to receive tibioperoneal angioplasty, and thus
their outcomes will be worse than expected compared to
randomized trial data.
Further monitoring of the BASIL patients for 2.5 years
reported that 56% of the population had died, 38% were
alive without amputation, and 7% were alive with amputa-
tion. Overall, the investigators demonstrated no significant
difference in amputation-free survival or overall survival
between the two strategies. However, for those patients
who survived for at least 2 years after randomization, a
bypass surgery first revascularization strategy was associated
with a significant increase in subsequent overall survival and
a trend toward improved amputation-free survival.11
Beyond limb salvage, in-hospital complications associ-
ated with tibioperoneal PTA and the poor overall survival
of this patient population is germane. Poor overall patient
survival has been demonstrated by Jamsen et al12 where
infrainguinal PTA in patients with CLI resulted in accept-
able limb salvage with a low number of additional revascu-
larization treatments, but poor patient survival. This study
of 100 consecutive patients demonstrated a major amputa-
tion rate of 32% with a 3-year survival rate of 41%. Romiti
et al13 performed a meta-analysis of infrapopliteal angio-
plasty for chronic critical limb ischemia to assess the middle
term outcomes after crural angioplasty. They utilized data
from 30 articles published from 1990 through 2006 and
stated that the results at 1 and 36 months were approxi-
mately 77% and 49% for primary patency. They concluded
that technical success and subsequent durability of crural
angioplasty are limited compared with bypass surgery, but
the clinical benefit is acceptable because limb salvage rates
are equivalent to bypass surgery.
Other authors have also reported that percutaneous
infrainguinal revascularization carries a low risk of morbid-
ity and mortality, and should be considered first-line ther-
apy in patients with CLI.13,14 Faglia et al15 reported a low
rate of complications with only a rate of 3.4%. Romiti et al13
in the meta-analysis reported that all procedure-related
complications were 7.8%. Contrary to these studies, we
report higher rates of complications. Renal complications
(8.1%), respiratory complications (5.1%), and cardiac com-
plications (3.2%) occurred after tibioperoneal PTA. We
have also demonstrated that 2.78% died during their initial
hospitalization and the 30-day mortality was 6.73%. Al-
though the complications we report were primarily acute
events coded within the data set as “complications of lurgical and/or medical care,” the possibility of some di-
gnoses being present on admission cannot be entirely
xcluded.
This analysis demonstrated that renal failure was asso-
iated with greater mortality in the tibioperoneal angio-
lasty population. The impact of the patient who is in the
ialysis-dependent population on infrainguinal revascular-
zation has also been evaluated demonstrating that ad-
anced age and number of years on dialysis correlated with
oorer outcomes.16 This is further supported by a multi-
ariate analysis showing that isolated tibioperoneal disease
s not an independent predictor of poor outcome after
ontrolling for confounding factors, of which tissue loss
nd end-stage renal disease correlate most consistently with
oor outcomes.17
Gender and racial disparities after tibioperoneal PTA
re also noted from this study. This population level anal-
sis after adjustment for risk factors has demonstrated that
omen, African Americans, patients with CHF, and pa-
ients with complicated diabetes were at increased risk for
mputation. After adjustment, female gender and African
merican race were associated with higher amputation
ates above the knee. Of note in this analysis, is that patients
ndergoing multilevel/tibioperoneal PTA were more
ikely to have 30-day amputations. Overall, women were
ore likely to undergomultilevel/tibioperoneal PTA com-
ared to men suggesting that they may have had more
dvanced disease or later presentation leading to increased
bove the knee amputations. We have also demonstrated
hat female gender was associated with greater in-hospital
nd 30-day mortality. Suggested reasons for the racial
isparities for amputation in African Americans may be
econdary to diabetes-related lower-extremity amputa-
ions, as authors have demonstrated that minorities had
oth a higher incidence and proportion of diabetes-related
mputations.18
Limitations of this study include the potential selection
ias based on limited coding schemes as well as confound-
ng by indication for the procedures performed. The Medi-
are data are administrative discharge data for billing pur-
oses and clinical information is limited by the ICD-9 and
PT codes. It is possible that the definition of indications
nd coding may vary within the data set and may vary
etween institutions and hospital coders. Certain compli-
ations mat not be appropriately captured in administrative
ata such as hematomas and is a limitation of administrative
ata. Another limitation of this observational epidemio-
ogic analysis is that confounding by indication may have
ccurred as the study is not randomized and the indication
or treatment may be biased related to the risk of future
ealth outcomes. Therefore, sicker patients may have been
referentially treated with angioplasty skewing the results
oward amputation. There is a bias in this study as all the
rocedures were performed in hospitals and no outpatient
acilities are contained within the data set. There continues
o be a rapid expansion of technology and its impact on
utcome and this study is only reflective of the years ana-
yzed. Finally, limb laterality cannot be determined by the
11
1
1
1
1
1
1
1
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Volume 54, Number 1 Vogel et al 115CPT code, and the differentiation of planned staged pro-
cedures or amputations vs unplanned procedures cannot be
determined from administrative data. Although refined
clinical data are not possible from administrative data, this
study describes the rates of procedures, amputations, and
readmissions on thousands of Medicare patients in the
community at large.
In conclusion, tibioperoneal angioplasty was associated
with high rates of readmission and amputation in the US
Medicare population. This information must be tempered
as this is not a randomized trial, but a descriptive and
natural history analysis utilizing all Medicare patients
treated by varied practitioners in the community at-large.
Many of the patients may have been deemed unfit for other
interventions to prevent amputation and received tibioper-
oneal angioplasty. Further detailed analysis of subgroups
with the highest readmission and amputation rates is re-
quired. Future analysis allowing for comparative effective-
ness of open bypass to tibial angioplasty and further
delineation of groups at greatest risk for failure after tib-
ioperoneal angioplasty is needed.
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